… In patients with COPD, QVA149 has demonstrated rapid and sustained bronchodilation, …
” [12] that dual bronchodilation with QVA149 will provide additional therapeutic benefits …

… We investigated the safety and efficacy of QVA149 over … -bronchodilator FEV 1 : 57.4%
predicted, 83.5% completed study. A smaller percentage of patients discontinued in the QVA149 …

… QVA149 IGNITE clinical programme [20–22] also demonstrate the overall benefits of dual
bronchodilation … In this study QVA149 was well tolerated with an adverse event profile similar …

… Objectives: QVA149 is a dual bronchodilator, containing a … QVA149 (440/200 µg) at 4-fold
the therapeutic dose for causing cardiac pharmacodynamic (PD) effects. Methods: This double-…

… The dual bronchodilator QVA149 was superior in preventing … single longacting antimuscarinic
bronchodilator glycopyrronium, … These results indicate the potential of dual bronchodilation …

… QVA149, indacaterol, and glycopyrronium of ≥3 months with at least two of the following
treatment groups: QVA149 … The overall hazard ratio (HR) for QVA149 versus placebo showed …

… with different mechanism of action optimizes bronchodilation and may reduce the risk of
exacerbations. QVA149 is a novel dual bronchodilator containing a fixed-dose combination of …

… Symptom control in COPD is essential and evidence shows that dual bronchodilation with
QVA149 brings benefits when compared to tiotropium. The use of QVA149 in symptomatic …

… , QVA149 was significantly superior to LAMAs for reducing all types of exacerbation. In
conclusion, several years after introduction of dual bronchodilation, … ® device (QVA149) has been …

… Fixed dose combination (FDC) dual bronchodilators that co-… dual bronchodilators include
QVA149 and umeclidinium/vilanterol (UMEC/VI). Long term clinical trials show that QVA149 …